Clinically isolated syndromes suggestive of multiple sclerosis, part 1: natural history, pathogenesis, diagnosis, and prognosis

被引:409
作者
Miller, D [1 ]
Barkhof, F
Montalban, X
Thompson, A
Filippi, M
机构
[1] UCL, Inst Neurol, Dept Neuroinflammat, MS NMR Res Unit, London WC1N 3BG, England
[2] VU Med Ctr, Dept Neuroradiol, Amsterdam, Netherlands
[3] Hosp Valle De Hebron, Dept Neuroimmunol, Barcelona, Spain
[4] Univ Milan, Osped San Raffaele, I-20127 Milan, Italy
[5] Inst Sci, Neuroimaging Res Unit, Milan, Italy
关键词
D O I
10.1016/S1474-4422(05)70071-5
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
In 85% of young adults with multiple sclerosis (MS), onset is a subacute clinically isolated syndrome (CIS) of the optic nerves, brainstem, or spinal cord. Methods of assessing the prognosis for patients who present with a CIS have been sought, because only 30-70% of patients with a CIS develop MS. When clinically silent brain lesions are seen on MRI, the likelihood of developing MS is high. MS can be diagnosed within 3 months of CIS presentation with certain MRI and CSF criteria. Disability from MS is less likely in patients with a CIS of optic neuritis or sensory symptoms only, few or no MRI lesions, a long period to the first relapse, and no disability after the first 5 years. Development of more reliable prognostic markers will enable new treatments to be targeted for those who are most likely to benefit. We encourage continued clinical and laboratory assessment of patients with a CIS.
引用
收藏
页码:281 / 288
页数:8
相关论文
共 70 条
[1]  
[Anonymous], 1970, Handbook of clinical neurology
[2]   Validation of diagnostic magnetic resonance imaging criteria for multiple sclerosis and response to interferon β1a [J].
Barkhof, F ;
Rocca, M ;
Francis, G ;
van Waesberghe, JHTM ;
Uitdehaag, BMJ ;
Hommes, OR ;
Hartung, HP ;
Durelli, L ;
Edan, G ;
Fernández, O ;
Seeldrayers, P ;
Sorensen, P ;
Margrie, S ;
Rovaris, M ;
Comi, G ;
Filippi, M .
ANNALS OF NEUROLOGY, 2003, 53 (06) :718-724
[3]   Comparison of MRI criteria at first presentation to predict conversion to clinically definite multiple sclerosis [J].
Barkhof, F ;
Filippi, M ;
Miller, DH ;
Scheltens, P ;
Campi, A ;
Polman, CH ;
Comi, G ;
Ader, HJ ;
Losseff, N ;
Valk, J .
BRAIN, 1997, 120 :2059-2069
[4]   Relapsing and remitting multiple sclerosis: Pathology of the newly forming lesion [J].
Barnett, MH ;
Prineas, JW .
ANNALS OF NEUROLOGY, 2004, 55 (04) :458-468
[5]   THE EFFECT OF CORTICOSTEROIDS FOR ACUTE OPTIC NEURITIS ON THE SUBSEQUENT DEVELOPMENT OF MULTIPLE-SCLEROSIS [J].
BECK, RW ;
CLEARY, PA ;
TROBE, JD ;
KAUFMAN, DI ;
KUPERSMITH, MJ ;
PATY, DW ;
BROWN, CH .
NEW ENGLAND JOURNAL OF MEDICINE, 1993, 329 (24) :1764-1769
[6]  
Beck RW, 2003, ARCH OPHTHALMOL-CHIC, V121, P944
[7]   Antimyelin antibodies as a predictor of clinically definite multiple sclerosis after a first demyelinating event [J].
Berger, T ;
Rubner, P ;
Schautzer, F ;
Egg, R ;
Ulmer, H ;
Mayringer, I ;
Dilitz, E ;
Deisenhammer, F ;
Reindl, M .
NEW ENGLAND JOURNAL OF MEDICINE, 2003, 349 (02) :139-145
[8]   Development of biomarkers in multiple sclerosis [J].
Bielekova, B ;
Martin, R .
BRAIN, 2004, 127 :1463-1478
[9]   Spinal cord abnormalities in recently diagnosed MS patients [J].
Bot, JCJ ;
Barkhof, F ;
Polman, CH ;
Nijeholt, GJLA ;
de Groot, V ;
Bergers, E ;
Ader, HJ ;
Castelijns, JA .
NEUROLOGY, 2004, 62 (02) :226-233
[10]   A longitudinal study of abnormalities on MRI and disability from multiple sclerosis [J].
Brex, PA ;
Ciccarelli, O ;
O'Riordan, JI ;
Sailer, M ;
Thompson, AJ ;
Miller, DH .
NEW ENGLAND JOURNAL OF MEDICINE, 2002, 346 (03) :158-164